MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$2.90 USD
-0.03 (-1.02%)
Updated Jun 14, 2024 02:29 PM ET
4-Sell of 5 4
A Value B Growth D Momentum A VGM
Brokerage Reports
MEI Pharma, Inc. [MEIP]
Reports for Purchase
Showing records 101 - 120 ( 141 total )
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences - Upcoming Events for the Week of June 30
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Good Early Responses for Pracinostat in Front-Line AML in the Elderly, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Good Early Responses for Pracinostat in Front- Line AML in the Elderly
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Pracinostat Clears Hurdle; Looking Forward to ASH; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
F3Q14 Results; Prepping for Important Pracinostat Data Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Study of ME-344 in SCLC and Ovarian Cancer Begins
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Important Study Start for ''344; Critical Pracinostat Data Later this Year
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Potential Biomarker Could Drive Solid Tumor Strategy; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Pracinostat Granted Orphan Designation; Catalysts in 2014; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Fiscal Q2:14 Results, Phase II Pracinostat Studies on Track, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
ASH and Analyst Day Wrap-Up, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
ASH and Analyst Day Wrap-Up, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.